


Preclinical efficacy of DM002, a bispecific HER3×MUC1-C antibody-drug conjugate with DNA topoisomerase I inhibitor, in solid tumor models

Yifu Zhang¹, Chengzhang Shang¹, Nannan Wang², Haochen Wei^{1,2}, Gao An¹, Chaoshe Guo¹, W. Frank An¹, Yi Yang¹









¹Biocytogen Pharmaceuticals (Beijing) Co., Ltd., Beijing, Beijing, China ²Doma Biopharmaceutical (Suzhou) Co., Ltd., Suzhou, China